U.S. markets closed

AXIM Biotechnologies, Inc. (AXIM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4300-0.0100 (-2.27%)
At close: 3:53PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4400
Open0.4400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4200 - 0.4555
52 Week Range0.1000 - 1.4400
Volume280,111
Avg. Volume183,032
Market Cap53.835M
Beta (5Y Monthly)-0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.0570
Earnings DateMay 01, 2018 - May 07, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies
    GlobeNewswire

    AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies

    SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has released a preprint of its manuscript describing the development of ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. The manuscript is co-authored by several executives of AXIM’s subsidiary Sapphire Biotech, Inc., including Chief Clinical Officer Douglas F. Lake, Chief Scientific Officer Sergei Svarovsky and Chief Technology Officer Alim Seit-Nebi.“This pandemic has caused massive economic and social unrest, not to mention the terrible loss of life and loved ones for millions of Americans. As COVID-19 vaccines roll out, recipients need to consistently monitor their levels of protective neutralizing antibodies. If vaccine-induced neutralizing antibodies decrease when compared to baseline, a vaccine booster may be necessary to keep everyone protected and prevent the spread of the virus. You can perform our test to indicate your level of protection while you drink your morning coffee. It’s fast, accurate, portable, and affordable when compared to similar tests,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech.Neutralizing antibodies are pivotal in halting the spread of the virus as they prevent the COVID-19 virus from infecting cells. As the world begins receiving the COVID-19 vaccine, recipients are reporting varying levels of neutralizing antibodies as each body responds differently to the vaccine. For this reason, it is important for recipients to measure their neutralizing antibodies regularly in order to know if and when it is time for a booster dose.AXIM’s ImmunoPass can serve as a convenient and effective testing option, as it has been proven to have 98 percent accuracy in detecting neutralizing antibodies using the benchmark of actual SARS-CoV-2 neutralization assays performed in a BSL3 laboratory.The advantages of AXIM’s ImmunoPass include that it uses only a single drop of blood, is smaller than the palm of a hand, highly portable, semi-quantitative, less expensive than a laboratory-based blood test, and can be used longitudinally to monitor increases and decreases in protective immunity after either natural infection or vaccine.To read the full manuscript, please visit: https://www.medrxiv.org/content/10.1101/2020.12.15.20248264v1.full.pdf.About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.Forward-Looking StatementsThe statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on May 13, 2020 and our subsequent quarterly report on Form 10-Q filed on June 30, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.comAXIM Corporate Contact Info: 6191 Cornerstone Ct., Ste. 114 San Diego, CA 92121, USA P. 858-923-4422Investor Relations Contact: investors@aximbiotech.com 888-759-0844

  • AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies
    GlobeNewswire

    AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies

    SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed an amended Emergency Use Authorization (EUA) application with the US Food and Drug Administration (FDA). AXIM first filed the EUA in September for measuring COVID-19 neutralizing antibodies in plasma and serum through its rapid diagnostic test. The Company amended the EUA to include positive results from a Biosafety Level 3 (BSL-3) live virus test that positively correlates the rapid 10-minute lateral flow assay test that accurately detects and measures levels of functional COVID-19 neutralizing antibodies in plasma.According to a receiver operating characteristic (ROC) curve, AXIM’s ImmunoPass shows 97.8 percent accuracy in detecting neutralizing antibodies. In comparison, Ortho Clinical Diagnostics’ VITROS® Total an IgG COVID-19 Antibody Test, which is FDA authorized and considered the gold standard, shows 85.8 percent accuracy.AXIM® Biotech CEO John W. Huemoeller II commented: “With this amended EUA, we are one step closer to our goal of providing an ‘Immunity Passport’ through our accurate, fast and relatively inexpensive COVID-19 neutralizing antibody test. Our assay is the only functional test that measures levels of neutralizing antibodies in serum, plasma or whole blood. In addition, it is portable and delivers results in less than 10 minutes. Once approved, it can serve as a reliable option for point-of-care providers and recipients aiming to confirm the durability of vaccine-induced immunity.”As the world begins administering COVID-19 vaccines, healthcare stakeholders will be able to employ AXIM’s rapid, point-of-care test to evaluate protective immune responses in vaccine recipients to ensure that vaccines elicit high levels of neutralizing antibodies. And as time goes on, AXIM’s test can help monitor vaccine-induced protection to see if future boosters are needed. A second application is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and given to patients fighting COVID-19.In August of this year, AXIM signed an exclusive limited licensing, manufacturing and distribution agreement with Empowered Diagnostics LLC (“Empowered Diagnostics”) for high volume production of the Company’s rapid diagnostic test. Under this agreement, Empowered Diagnostics will manufacture the lateral flow assays under the name “ImmunoPass”. With the filing of this EUA the Company is now able to sell to clinics for use in plasma and/or serum immediately.About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.Forward-Looking StatementsThe statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on May 13, 2020 and our subsequent quarterly report on Form 10-Q filed on June 30, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.comAXIM Corporate Contact Info: 6191 Cornerstone Ct., Ste. 114 San Diego, CA 92121, USA P. 858-923-4422Investor Relations Contact: investors@aximbiotech.com 888-759-0844

  • AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14
    GlobeNewswire

    AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14

    SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s CEO John W. Huemoeller II will be presenting at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020, at 11:00 a.m. PST/2:00 p.m. EST. During the 10-minute presentation, Huemoeller will discuss AXIM’s COVID-focused research and testing tools, including an update on progress around the Company’s Emergency Use Authorization (EUA) application on its rapid point-of-care COVID-19 neutralizing antibody test. Directly following his presentation, Huemoeller will take questions from a panel of investors and analysts.AXIM® Biotech CEO John W. Huemoeller II commented: “As we move close to having the first COVID-19 vaccines available in the U.S., our rapid COVID-19 neutralizing antibody test can serve as an easy, quick and relatively inexpensive way for researchers to determine the efficacy of their vaccines. I look forward to presenting on this topic and the other highlights of AXIM’s COVID-focused research during the LD Micro Main Event investor conference.”To register for the conference, visit ve.mysequire.com/. The LD Micro Main Event investor conference will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.Forward-Looking StatementsThe statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on May 13, 2020 and our subsequent quarterly report on Form 10-Q filed on June 30, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.comAXIM Corporate Contact Info: 6191 Cornerstone Ct., Ste. 114 San Diego, CA 92121, USA P. 858-923-4422Investor Relations Contact: investors@aximbiotech.com 888-759-0844